33 results about "Promoter enhancer" patented technology

A method and vectors for controlling blood glucose levels in a mammal are disclosed. In one embodiment, the method comprises the steps of: treating the hepatocyte cells of a patient with a first, second or third vector, wherein the first vector comprises a promoter enhancer, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase and an albumin 3′UTR and lacks an HGH intron, wherein the second vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site and an albumin 3′UTR and lacks a promoter enhancer, wherein the third vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site, an albumin 3′UTR and a promoter enhancer and observing the patient's insulin levels, wherein the patient's insulin levels are controlled.

The invention relates to a genetically modified mesenchymal stem cell (MSC) and medical use thereof in the treatment of tumours, said MSC comprising one or more exogenous nucleic acid molecule(s), wherein said exogenous nucleic acid molecule(s) comprise a region encoding one or more immune response-stimulating or immune response-modulating cytokine(s) operably linked to a promoter or promoter / enhancer combination. The invention encompasses the use of said cells in modulating the tumour microenvironment in order to attract immune effector cells and facilitate their activation and / or adoption of a memory phenotype. One aspect of the invention relates to the use of said cells in anti-tumour treatment comprising the combined administration of said mesenchymal stem cells with anti-tumour immunotherapies, such as checkpoint inhibitors, immune cells, for example T cells, such as T cells with artificial T cell receptors, for example a chimeric antigen receptor (CAR-Ts) or exogenous T-Cell Receptor (TCR) transduced cells, NK cells or macrophages / monocytes, or a cancer vaccine.

The present invention provides polynucleotide molecules useful for expressing transgenes in plants. More particularly, the present invention provides chimeric promoters comprising a Cauliflower mosaic virus 35S promoter enhancer fused with a plant actin gene promoter. The present invention also provides expression constructs containing the chimeric promoter. The present invention also provides transgenic plants and seeds containing the chimeric promoter.

This invention provides a method for treating a subject afflicted with a tumor using genetically modified mesenchymal stem cells, wherein each genetically modified mesenchymal stem cell contains an exogenous nucleic acid comprising (i) a cytotoxic protein-encoding region operably linked to (ii) a promoter or promoter / enhancer combination, whereby the cytotoxic protein is selectively expressed when the genetically modified mesenchymal stem cells come into proximity with the tumor's stromal tissue. This invention further provides genetically modified mesenchymal stem cells for use in this method.

The invention provides methods and compositions for assembling a modular replacement genome in a host microorganism. After such assembly, the host organism's genome is inactivated or ablated to permit full control of host cellular functions by the replacement genome. A modular replacement genome comprises an assembly of nucleic acid fragments, or segments, derived from one or more natural organisms or from synthetic polynucleotides or from a combination of both. Such an assembly, or set, of segments making up a replacement genome comprises a substantially complete set of genes and regulatory elements for carrying out minimal life functions under predefined culture conditions. The invention provides modular genomes having modules that are amenable to facile replacement, deletion, and / or additions. Such modules may be synthetic polynucleotides and may be designed for controlling gene content, excluding of genes that encode inhibitors or otherwise undesirable competing enzymes that divert a host cell from desired metabolic / synthetic processes; modifying codon usage to maximize or minimize protein production; modifying regulatory elements, including promoters, enhancers, repressors, activator, or the like, to modulate gene expression; balancing enzymatic and transport activities to optimize fluxes of substrates, intermediates, and products in metabolic pathways, and like objectives.

A method for improving the replication of a covalently closed circular plasmid is provided. The method includes providing a covalently closed circular plasmid having a Pol I-dependent origin of replication, and an insert including a structured DNA sequence selected from the group consisting of inverted repeat sequence, direct repeat sequence, homopolymeric repeat sequence, eukaryotic origin of replication or eukaryotic promoter enhancer sequence, wherein the structured DNA sequence is located at a distance of less than 1000 bp from the Pol I-dependent origin of replication in the direction ofreplication. The method also includes modifying the covalently closed circular recombinant molecule such that the Pol I-dependent origin of replication is replaced with a Pol III-dependent origin of replication, whereby the resultant Pol III-dependent origin of replication covalently closed circular plasmid has improved replication. An antibiotic marker free covalently closed circular recombinantDNA molecule is also provided.

The present invention relates to a highly efficient eukaryotic expression vector containing an exogenous transcription regulatory element which comprises a promoter / enhancer and the nucleotide sequence upstream of the translation initiation codon derived from human cytomegalovirus (HCMV) immediately early (IE) gene or human elongation factor 1α (EF1α) gene.

The current invention reports a promoter that has the nucleic acid sequence of SEQ ID NO: 02 or SEQ ID NO: 03 which is a human CMV major immediate-early (hCMV-MIE) promoter / enhancer with C to G point mutation at position −41 and / or −179 relative to the transcription start site. This new promoter is especially useful for the production of polypeptides at large scale as it shows reduced promoter silencing and improved polypeptide production.

An object of the present invention is to provide a method for increasing the expression of foreign genes, in particular, using a promoter, an enhancer, and the like, and an expression cassette containing a promoter, an enhancer, and the like, by which gene expression can be increased. The purpose is achieved with the use of the gene expression cassette comprising a DNA construct containing a gene to be expressed and a poly A addition sequence that are located downstream of a 1st promoter, and further comprising an enhancer or a 2nd promoter ligated downstream of the DNA construct.

Provided is an expression vector for gene therapy. The expression vector comprises a new combination which contains a transcriptional control element and comprises a promoter, an enhancer, an intron, an untranslated region (UTR) and a loca control region (LCP). The expression vector can continuously express specific genes of hepatic tissue so that the expression vector can be effectively used in treating thrombus forming, hemophilia, liver cancer and the like.

The invention relates to a lentivirus packaging vector system, a lentivirus, a construction method thereof, and a kit. The lentiviral packaging vector system consists of two or more plasmids, which can produce lentiviruses with only one infection ability but no replication ability. One of the plasmids contains sequentially linked promoters, enhancers, and encoding envelope proteins A nucleic acid fragment, the nucleic acid fragment encoding the envelope protein comprises a nucleic acid fragment for expressing the S protein of SARS-CoV-2 or a nucleic acid fragment for expressing a mutant of the S protein of SARS-CoV-2, for expressing SARS-CoV-2 The mutant of the S protein of CoV-2 is that the 614th amino acid at the C-terminus of the S1 subunit of the S protein of SARS-CoV-2 is mutated from aspartic acid to glycine. The lentivirus prepared by the above-mentioned lentiviral packaging vector system can be used to screen drugs against SARS-CoV-2 or its mutant strains, and has high safety.

This invention provides a variety of novel adeno-associated virus (AAV) vectors for gene therapy applications in the treatment of glycogen storage disease type la (GSD-Ia). Disclosed herein are a number of recombinant nucleic acid molecules, vectors and recombinant AAV that incorporate a modified G6PC promoter / enhancer sequence. Utilization of the modified G6PC promoter / enhancer sequence results in enhanced AAV yield and quality when expressed from various host cell platforms. Also provided herein are compositions comprising the novel AAV of the invention and methods of treating GSD-Ia using the same.